Abnormal involuntary movement (AIM) expression following D2 dopamine agonist challenge is determined by the nature of prior dopamine receptor stimulation (priming) in 6-hydroxydopamine lesioned rats

Pharmacology Biochemistry and Behavior

Volumn 105, Issue , 2013, Pages 26-33

  Drake, Jonathan D ^a   Kibuuka, Laura N ^a   Dimitrov, Kroum D ^a   Pollack, Alexia E ^a  

^a UNIVERSITY OF MASSACHUSETTS BOSTON   (United States)

Author keywords

6 Hydroxydopamine; Abnormal involuntary movements (AIM); Behavioral sensitization; D1 dopamine; D2 dopamine

Indexed keywords

2,3,4,5 TETRAHYDRO 7,8 DIHYDROXY 1 PHENYL 1H 3 BENZAZEPINE; APOMORPHINE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; OXIDOPAMINE; PROTEIN FOS; QUINPIROLE; WATER;

ANIMAL EXPERIMENT; ARTICLE; CIRCLING BEHAVIOR; CONTROLLED STUDY; DRUG SENSITIZATION; DYSKINESIA; GROOMING; LOCOMOTION; MALE; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT;

2,3,4,5-TETRAHYDRO-7,8-DIHYDROXY-1-PHENYL-1H-3-BENZAZEPINE; ANIMALS; BEHAVIOR, ANIMAL; DOPAMINE AGONISTS; MALE; MOVEMENT; OXIDOPAMINE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, DOPAMINE D2;

RATTUS;

EID: 84874134783     PISSN: 00913057     EISSN: 18735177     Source Type: Journal    
DOI: 10.1016/j.pbb.2013.01.014     Document Type: Article

References (53)

1. C.H. Adler, K.D. Sethi, R.A. Hauser, T.L. Davis, J.P. Hammerstad, and J. Bertoni Ropinirole for the treatment of early Parkinson's disease. The Ropinirole Study Group Neurology 49 1997 393 399 (Pubitemid 27368872)
2. K.E. Asin, L. Bednarz, A. Nikkel, and R. Perner Rotation and striatal c-Fos expression after repeated, daily treatment with selective dopamine receptor agonists and levodopa J Pharmacol Exp Ther 273 1995 1483 1490
3. I. Aubert, C. Guigoni, K. Hakansson, Q. Li, S. Dovero, and N. Barthe Increased D1 dopamine receptor signaling in levodopa-induced dyskinesia Ann Neurol 57 2005 17 26 (Pubitemid 40053311)
4. A. Berthet, G. Porras, E. Doudnikoff, H. Stark, M. Cador, and E. Bezard Pharmacological analysis demonstrates dramatic alteration of D1 dopamine receptor neuronal distribution in the rat analog of l-DOPA-induced dyskinesia J Neurosci 29 2009 4829 4835
5. E. Bezard, J.M. Brotchie, and C.E. Gross Pathophysiology of levodopa-induced dyskinesia: potential for new therapies Nat Rev Neurosci 8 2001 577 588 (Pubitemid 33679831)
6. R. Bordet, S. Ridray, S. Carboni, J. Diaz, P. Sokoloff, and J.C. Schwartz Induction of dopamine D3 receptor expression as a mechanism of behavioral sensitization to levodopa Proc Natl Acad Sci USA 94 1997 3363 3367 (Pubitemid 27157317)
7. F. Calon, M. Goulet, P.J. Blanchet, J.C. Martel, M.F. Piercey, and P.J. Bedard Levodopa or D2 agonist induced dyskinesia in MPTP monkeys: correlation with changes in dopamine and GABAA receptors in the striatopallidal complex Brain Res 680 1995 43 52
8. F. Calon, M. Morissette, M. Goulet, R. Grondin, P.J. Blanchet, and P.J. Bedard Chronic D1 and D2 dopaminomimetic treatment of MPTP-denervated monkeys: effects on basal ganglia GABA(A)/benzodiazepine receptor complex and GABA content Neurochem Int 35 1999 81 91 (Pubitemid 29251232)
9. R.J. Carey Chronic l-dopa treatment in the unilateral 6-OHDA rat: evidence for behavioral sensitization and biochemical tolerance Brain Res 568 1991 205 214
10. M. Carta, and E. Bezard Contribution of pre-synaptic mechanisms to l-DOPA-induced dyskinesia Neuroscience 198 2011 245 251
11. A.R. Carta, A. Pinna, O. Cauli, and M. Morelli Differential regulation of GAD67, enkephalin and dynorphin mRNAs by chronic-intermittent l-dopa and A2A receptor blockade plus l-dopa in dopamine-denervated rats Synapse 44 2002 166 174 (Pubitemid 34303914)
12. A.R. Carta, L. Frau, A. Pinna, S. Pontis, N. Simola, and N. Schintu Behavioral and biochemical correlates of the dyskinetic potential of dopaminergic agonists in the 6-OHDA lesioned rat Synapse 62 2008 524 533 (Pubitemid 351794179)
13. A.R. Carta, L. Frau, S. Pontis, A. Pinna, and M. Morelli Direct and indirect striatal efferent pathways are differentially influenced by low and high dyskinetic drugs: behavioural and biochemical evidence Parkinsonism Relat Disord 14 Suppl. 2 2008 S165 S168
14. M.A. Cenci, C.S. Lee, and A. Bjorklund l-DOPA-induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin- and glutamic acid decarboxylase mRNA Eur J Neurosci 10 1998 2694 2706 (Pubitemid 28362576)
15. M.A. Delfino, A.V. Stefano, J.E. Ferrario, I.R. Taravini, M.G. Murer, and O.S. Gershanik Behavioral sensitization to different dopamine agonists in a parkinsonian rodent model of drug-induced dyskinesias Behav Brain Res 152 2004 297 306 (Pubitemid 38757900)
16. B. Dumartin, I. Caille, F. Gonon, and B. Bloch Internalization of D1 dopamine receptor in striatal neurons in vivo as evidence of activation by dopamine agonists J Neurosci 18 1998 1650 1661 (Pubitemid 28103073)
17. T.M. Engber, C. Marin, Z. Susel, and T.N. Chase Differential effects of chronic dopamine D1 and D2 receptor agonists on rotational behavior and dopamine receptor binding Eur J Pharmacol 236 1993 385 393 (Pubitemid 23170379)
18. S. Gancher, and A. Mayer Sensitization to apomorphine-induced rotational behavior in 6-OHDA-lesioned rats: effects of NMDA antagonists on drug response Brain Res 682 1995 63 68
19. C.E. Gross, P. Ravenscroft, S. Dovero, M. Jaber, B. Bioulac, and E. Bezard Pattern of levodopa-induced striatal changes is different in normal and MPTP-lesioned mice J Neurochem 84 2003 1246 1255 (Pubitemid 36343591)
20. C. Guigoni, I. Aubert, Q. Li, V.V. Gurevich, J.L. Benovic, and S. Ferry Pathogenesis of levodopa-induced dyskinesia: focus on D1 and D3 dopamine receptors Parkinsonism Relat Disord 11 Suppl. 1 2005 S25 S29
21. B. Henry, A.R. Crossman, and J.M. Brotchie Effect of repeated l-DOPA, bromocriptine, or lisuride administration on preproenkephalin-A and preproenkephalin-B mRNA levels in the striatum of the 6-hydroxydopamine-lesioned rat Exp Neurol 155 1999 204 220 (Pubitemid 29124714)
22. M.J. Hurley, and P. Jenner What has been learnt from study of dopamine receptors in Parkinson's disease? Pharmacol Ther 111 2006 715 728 (Pubitemid 44118432)
23. P. Jenner Molecular mechanisms of l-DOPA-induced dyskinesia Nat Rev Neurosci 9 2008 665 677
24. R. Kumar, L.R. Riddle, S.A. Griffin, W. Chu, S. Vangveravong, and J. Neisewander Evaluation of D2 and D3 dopamine receptor selective compounds on l-dopa-dependent abnormal involuntary movements in rats Neuropharmacology 56 2009 956 969
25. E.L. Lane, C.S. Daly, G.A. Smith, and S.B. Dunnett Context-driven changes in l-DOPA-induced behaviours in the 6-OHDA lesioned rat Neurobiol Dis 42 2011 99 107
26. C.S. Lee, M.A. Cenci, M. Schulzer, and A. Bjorklund Embryonic ventral mesencephalic grafts improve levodopa-induced dyskinesia in a rat model of Parkinson's disease Brain 123 2000 1365 1379 (Pubitemid 30420937)
27. M. Lundblad, M. Andersson, C. Winkler, D. Kirik, N. Wierup, and M.A. Cenci Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson's disease Eur J Neurosci 15 2002 120 132 (Pubitemid 35478015)
28. F. Mela, M. Marti, S. Bido, M.A. Cencit, and M. Morari In vivo evidence for a differential contribution of striatal and nigral D1 and D2 receptors to l-DOPA induced dyskinesias and the accompanying surge of nigral amino acid levels Neurobiol Dis 45 2012 573 582
29. C. Monville, E.M. Torres, and S.B. Dunnett Validation of the l-dopa-induced dyskinesia in the 6-OHDA model and evaluation of the effects of selective dopamine receptor agonists and antagonists Brain Res Bull 68 2005 16 23 (Pubitemid 41698872)
30. K.M. Nielsen, and J.J. Soghomonian Normalization of glutamate decarboxylase gene expression in the entopeduncular nucleus of rats with a unilateral 6-hydroxydopamine lesion correlates with increased GABAergic input following intermittent but not continuous levodopa Neuroscience 123 2004 31 42 (Pubitemid 37518473)
31. J.G. Nutt Levodopa-induced dyskinesia: review, observations, and speculations Neurology 40 1990 340 345 (Pubitemid 20099455)
32. C.W. Olanow The role of dopamine agonists in the treatment of early Parkinson's disease Neurology 58 2002 S33 S41
33. M.L. Paul, R.W. Currie, and H.A. Robertson Priming of a D1 dopamine receptor behavioural response is dissociated from striatal immediate-early gene activity Neuroscience 66 1995 347 359
34. G. Paxinos, and C. Watson The rat brain in stereotaxic coordinates 2nd ed. 1986 Academic Press San Diego
35. R.K. Pearce, T. Banerji, P. Jenner, and C.D. Marsden De novo administration of ropinirole and bromocriptine induces less dyskinesia than l-dopa in the MPTP-treated marmoset Mov Disord 13 1998 234 241 (Pubitemid 28127797)
36. M. Pinheiro-Carrera, C. Tomaz, J.P. Huston, H. Dai, and R.J. Carey 'Priming' enhances the relationship of striatal l-dopa concentration to behavior Neuroreport 5 1994 1665 1669 (Pubitemid 24265267)
37. A. Pinna, S. Pontis, and M. Morelli Expression of dyskinetic movements and turning behaviour in subchronic l-DOPA 6-hydroxydopamine-treated rats is influenced by the testing environment Behav Brain Res 171 2006 175 178 (Pubitemid 43728402)
38. A.E. Pollack, and L.I. Thomas D1 priming enhances both D1- and D2-mediated rotational behavior and striatal Fos expression in 6-hydroxydopamine lesioned rats Pharmacol Biochem Behav 94 2010 346 351
39. A.E. Pollack, and T.M. Yates Prior D1 dopamine receptor stimulation is required to prime D2-mediated striatal Fos expression in 6-hydroxydopamine- lesioned rats Neuroscience 94 1999 505 514 (Pubitemid 29436077)
40. A.E. Pollack, S.M. Turgeon, and J.S. Fink Apomorphine priming alters the response of striatal outflow pathways to D2 agonist stimulation in 6-hydroxydopamine-lesioned rats Neuroscience 79 1997 79 93 (Pubitemid 27245001)
41. O. Rascol, D.J. Brooks, A.D. Korczyn, P.P. De Deyn, C.E. Clarke, and A.E. Lang A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. 056 Study Group N Engl J Med 342 2000 1484 1491 (Pubitemid 30318272)
42. O. Rascol, J.G. Nutt, O. Blin, C.G. Goetz, J.M. Trugman, and C. Soubrouillard Induction by dopamine D1 receptor agonist ABT-431 of dyskinesia similar to levodopa in patients with Parkinson disease Arch Neurol 58 2001 249 254 (Pubitemid 32163162)
43. O. Rascol, D.J. Brooks, A.D. Korczyn, P.P. De Deyn, C.E. Clarke, and A.E. Lang Development of dyskinesias in a 5-year trial of ropinirole and l-dopa Mov Disord 21 2006 1844 1850 (Pubitemid 44848929)
44. L.R. Riddle, R. Kumar, S.A. Griffin, P. Grundt, A.H. Newman, and R.R. Luedtke Evaluation of the D3 dopamine receptor selective agonist/partial agonist PG01042 on l-dopa dependent animal involuntary movements in rats Neuropharmacology 60 2011 284 294
45. C. Rouillard, P.J. Bedard, P. Falardeau, and T. Dipaolo Behavioral and biochemical evidence for a different effect of repeated administration of l-dopa and bromocriptine on denervated versus non-denervated striatal dopamine receptors Neuropharmacology 26 1987 1601 1606 (Pubitemid 18008359)
46. K.D. Sethi, C.F. O'Brien, J.P. Hammerstad, C.H. Adler, T.L. Davis, and R.L. Taylor Ropinirole for the treatment of early Parkinson disease: a 12-month experience. Ropinirole Study Group Arch Neurol 55 1998 1211 1216
47. N. Simola, G. Di Chiara, W.M.U. Daniels, T. Schallert, and M. Morelli Priming of rotational behavior by a dopamine receptor agonist in hemiparkinsonian rats: movement-dependent induction Neuroscience 158 2009 1625 1631
48. L.A. Smith, M.J. Jackson, L. Johnson, M. Kuoppamaki, S. Rose, and G. Al-Barghouthy Switching from levodopa to the long-acting dopamine D2/D3 agonist piribedil reduces the expression of dyskinesia while maintaining effective motor activity in MPTP-treated primates Clin Neuropharmacol 29 2006 112 125 (Pubitemid 44503888)
49. J.L. Taylor, C. Bishop, and P.D. Walker Dopamine D1 and D2 receptor contributions to l-DOPA-induced dyskinesia in the dopamine-depleted rat Pharmacol Biochem Behav 81 2005 887 893 (Pubitemid 41187824)
50. B.C. Tel, B.Y. Zeng, C. Cannizzaro, R.K. Pearce, S. Rose, and P. Jenner Alterations in striatal neuropeptide mRNA produced by repeated administration of l-DOPA, ropinirole or bromocriptine correlate with dyskinesia induction in MPTP-treated common marmosets Neuroscience 115 2002 1047 1058 (Pubitemid 35351696)
51. U. Ungerstedt, and G.W. Arbuthnott Quantitative recording of rotational behavior in rats after 6-hydroxy-dopamine lesions of the nigrostriatal dopamine system Brain Res 24 1970 485 493
52. C.V. Vorhees, H.L. Johnson, L.N. Burns, and M.T. Williams Developmental treatment with the dopamine D2/3 agonist quinpirole selectively impairs spatial learning in the Morris water maze Neurotoxicol Teratol 31 2009 1 10
53. C. Winkler, D. Kirik, A. Bjorklund, and M.A. Cenci l-DOPA-induced dyskinesia in the intrastriatal 6-hydroxydopamine model of Parkinson's disease: relation to motor and cellular parameters of nigrostriatal function Neurobiol Dis 10 2002 165 186 (Pubitemid 34775470)